IV meloxicam

Phase 3Small molecule

UUniversity of Miami

IV meloxicam is one of 17 small molecule programs targeting Total Joint Arthroplasty. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Total Joint ArthroplastyActive, not recruiting

Total Joint ArthroplastyPhase 3

Active, not recruiting

Competition

Competitive Landscape

24 competitors in Total Joint Arthroplasty

#DrugCompanyPhaseTrials

Cyklokapron

AAmring

Approved

4 2

Benadryl

PParkedale

Approved

1 3

Fondaparinux Sodium

GSK

Approved

1 4

Xarelto

WWim Janssens

Approved

—5

Marinol

Alnylam Pharmaceuticals

Phase 3

1 6

Toradol

JJavelin Pharmaceuticals

Phase 3

1 7

Bayer Aspirin

Bayer

Phase 2

1 8

Circadin

NNeurim Pharmaceuticals Ltd.

Phase 1

3 9

Betadine

BBecton, Dickinson and Company

Phase 1

2 10

Oxycontin

PProtega

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Total Joint Arthroplasty1 trial

Meloxicam for Pain Management After Total Joint Arthroplasty (TJA)

Completed·UUniversity of Miami·Phase 3·NCT05291598·223 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for IV meloxicam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — IV meloxicam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for IV meloxicam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Miami company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Miami

IV meloxicam

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Total Joint Arthroplasty1 trial

References

Drug Info

Quick Facts

Related News